<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OIQ-16009039</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-08-17</date_registration>
      <primary_sponsor>The Second Affiliated Hospital of Chongqing Medical University</primary_sponsor>
      <public_title>The effect of allogeneic peripheral blood stem cell transplantation combined with intra-bone marrow injection on hematopoietic reconstruction and GVHD:  quasi-randomised controlled, single center clinical trial </public_title>
      <acronym />
      <scientific_title>The effect of allogeneic peripheral blood stem cell transplantation combined with intra-bone marrow injection on hematopoietic reconstruction and GVHD:  quasi-randomised controlled, single center clinical trial </scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-08-01</date_enrolment>
      <type_enrolment />
      <target_size>treatment group:20;control group:20;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=15221</url>
      <study_type>Observational study</study_type>
      <study_design>Quasi-randomized controlled</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>hematologic malignancy</hc_freetext>
      <i_freetext>treatment group:peripheral blood stem cells infusion + Intra-bone marrow injection;control group:peripheral blood stem cells infusion;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Shi-Feng Lou</firstname>
        <middlename />
        <lastname />
        <address>74 Linjiang Road, Chongqing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13508331213</telephone>
        <email>13508331213@163.com</email>
        <affiliation>The Second Affiliated Hospital of Chongqing Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Shi-Feng Lou</firstname>
        <middlename />
        <lastname />
        <address>74 Linjiang Road, Chongqing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13508331213</telephone>
        <email>13508331213@163.com</email>
        <affiliation>The Second Affiliated Hospital of Chongqing Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Male and female aged between 10 to 65 years;
2. clear diagnosis hematologic malignancy;
3. prepared for peripheral blood stem cell transplantation.</inclusion_criteria>
      <agemin>10</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Serious systemic organ dysfunction;
2. bone marrow  puncture point infection;
3. coagulation dysfunction.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Hematopoietic reconstitution time;the incidence of GVHD;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>transfusion requirement;Overall survival;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Provide their own</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Not approved</status>
        <approval_date>2013-08-26</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>